Maze Financial Statements From 2010 to 2026

MAZE Stock   45.03  1.08  2.46%   
Maze Therapeutics' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Maze Therapeutics' valuation are provided below:
Market Capitalization
2.1 B
Enterprise Value Revenue
369.0066
Earnings Share
(2.56)
There are over one hundred nine available fundamental ratios for Maze Therapeutics, which can be analyzed over time and compared to other ratios. Investors should ensure to check all of Maze Therapeutics' last-minute performance against the performance from 2010 to 2026 to make sure the company is sustainable down the road. The current year's Enterprise Value is expected to grow to about 688.4 M

Maze Therapeutics Total Revenue

202.26 Million

Check Maze Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Maze Therapeutics' main balance sheet or income statement drivers, such as Net Interest Income of 3.2 M, Interest Income of 3.2 M or Depreciation And Amortization of 3 M, as well as many indicators such as Price To Sales Ratio of 3.34, Dividend Yield of 0.0 or PTB Ratio of 3.88. Maze financial statements analysis is a perfect complement when working with Maze Therapeutics Valuation or Volatility modules.
  
Build AI portfolio with Maze Stock
Check out the analysis of Maze Therapeutics Correlation against competitors.

Maze Therapeutics Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets169.4 M276.6 M159.3 M
Slightly volatile
Short and Long Term Debt Total28.9 M24 M32.1 M
Very volatile
Other Current Liabilities10.3 M12.7 M14.1 M
Slightly volatile
Total Current Liabilities15.4 M18.6 M20.1 M
Slightly volatile
Total Stockholder Equity237.8 M226.4 M117.1 M
Slightly volatile
Property Plant And Equipment Net28.3 M26.9 M38.6 M
Slightly volatile
Accounts PayableM2.2 M1.7 M
Slightly volatile
Cash119.5 M226.3 M110 M
Slightly volatile
Non Current Assets Total32 M35 M41.9 M
Slightly volatile
Non Currrent Assets Other9.5 MM2.7 M
Slightly volatile
Cash And Short Term Investments119.5 M226.3 M110 M
Slightly volatile
Common Stock Shares Outstanding48.2 M50.4 M44.4 M
Slightly volatile
Liabilities And Stockholders Equity169.4 M276.6 M159.3 M
Slightly volatile
Non Current Liabilities Total25.6 M20.7 M27.9 M
Very volatile
Capital Lease Obligations23.5 M24 M30.6 M
Slightly volatile
Other Current Assets4.3 M4.4 M5.9 M
Slightly volatile
Other Stockholder Equity30 M54.3 M18.8 M
Slightly volatile
Total Liabilities41 M39.3 M48 M
Pretty Stable
Property Plant And Equipment Gross39.1 M42.1 M49.3 M
Slightly volatile
Total Current Assets125.4 M231.9 M116.1 M
Slightly volatile
Capital Stock1.6 K1.8 KK
Slightly volatile
Net Working Capital104.2 M208.1 M95.3 M
Slightly volatile
Short Term Debt4.9 M5.3 M4.4 M
Slightly volatile
Common Stock1.7 K1.8 K17.7 K
Slightly volatile
Long Term Debt16.1 M18.1 M19.7 M
Slightly volatile
Non Current Liabilities Other775.2 K872.1 K951.9 K
Slightly volatile

Maze Therapeutics Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Net Interest Income3.2 M5.4 M2.4 M
Slightly volatile
Interest Income3.2 M5.4 M2.4 M
Slightly volatile
Depreciation And AmortizationMM3.7 M
Slightly volatile
Selling General Administrative27.1 M30.4 M23.8 M
Slightly volatile
Other Operating Expenses85.2 M98.9 M108 M
Slightly volatile
Research Development65.5 M75.1 M85 M
Slightly volatile
Cost Of RevenueMM3.7 M
Slightly volatile
Total Operating Expenses85.2 M98.9 M108 M
Slightly volatile
Reconciled DepreciationMM3.7 M
Slightly volatile
Income Tax Expense937.6 K1.1 M1.2 M
Slightly volatile

Maze Therapeutics Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation9.2 M11.1 M7.4 M
Slightly volatile
Begin Period Cash Flow25.9 M27.2 M165.1 M
Slightly volatile
Other Cashflows From Financing Activities82.6 M78.6 M14.8 M
Slightly volatile
DepreciationMM3.7 M
Slightly volatile
Other Non Cash Items10.2 M14.1 MM
Slightly volatile
Capital Expenditures947.7 KM1.7 M
Slightly volatile
Total Cash From Financing Activities112.1 M106.8 M20.6 M
Slightly volatile
End Period Cash Flow120.7 M227.6 M111.2 M
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio3.343.754.0969
Slightly volatile
PTB Ratio3.884.0810.0257
Pretty Stable
Book Value Per Share4.254.052.5382
Slightly volatile
Stock Based Compensation To Revenue0.04610.05180.0566
Slightly volatile
Capex To Depreciation0.350.40.4645
Slightly volatile
PB Ratio3.884.0810.0257
Pretty Stable
EV To Sales2.522.843.0986
Slightly volatile
Sales General And Administrative To Revenue0.130.140.155
Slightly volatile
Research And Ddevelopement To Revenue0.40.450.4898
Slightly volatile
Capex To Revenue0.00550.00620.0067
Slightly volatile
Cash Per Share4.254.042.5366
Slightly volatile
Income Quality0.851.310.9235
Slightly volatile
Current Ratio4.528.785.3849
Pretty Stable
Tangible Book Value Per Share4.254.052.5382
Slightly volatile
Graham Number8.789.8910.7897
Slightly volatile
Shareholders Equity Per Share4.254.052.5382
Slightly volatile
Debt To Equity0.150.160.5582
Pretty Stable
Capex Per Share0.02980.03010.04
Slightly volatile
Revenue Per Share3.063.443.757
Slightly volatile
Interest Debt Per Share0.90.70.7565
Pretty Stable
Debt To Assets0.120.130.2255
Very volatile
Price Book Value Ratio3.884.0810.0257
Pretty Stable
Pretax Profit Margin0.260.290.3137
Slightly volatile
Ebt Per Ebit1.091.071.0332
Very volatile
Operating Profit Margin0.270.310.3375
Slightly volatile
Effective Tax Rate0.01750.01980.0216
Slightly volatile
Company Equity Multiplier1.331.41.7812
Pretty Stable
Long Term Debt To Capitalization0.540.60.655
Slightly volatile
Total Debt To Capitalization0.130.140.2554
Very volatile
Debt Equity Ratio0.150.160.5582
Pretty Stable
Ebit Per Revenue0.270.310.3375
Slightly volatile
Quick Ratio4.528.785.3849
Pretty Stable
Net Income Per E B T0.780.880.9606
Slightly volatile
Cash Ratio4.38.575.0987
Pretty Stable
Operating Cash Flow Sales Ratio0.360.410.4454
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.11.131.0281
Slightly volatile
Price To Book Ratio3.884.0810.0257
Pretty Stable
Fixed Asset Turnover4.485.045.5
Slightly volatile
Debt Ratio0.120.130.2255
Very volatile
Price Sales Ratio3.343.754.0969
Slightly volatile
Asset Turnover0.560.630.6844
Slightly volatile
Net Profit Margin0.250.280.3063
Slightly volatile
Price Fair Value3.884.0810.0257
Pretty Stable

Maze Therapeutics Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap558.7 M628.7 M686 M
Slightly volatile
Enterprise Value688.4 M607.6 M631.6 M
Very volatile

Maze Fundamental Market Drivers

About Maze Therapeutics Financial Statements

Maze Therapeutics stakeholders use historical fundamental indicators, such as Maze Therapeutics' revenue or net income, to determine how well the company is positioned to perform in the future. Although Maze Therapeutics investors may analyze each financial statement separately, they are all interrelated. For example, changes in Maze Therapeutics' assets and liabilities are reflected in the revenues and expenses on Maze Therapeutics' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Maze Therapeutics Common. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Total Revenue192.6 M202.3 M
Cost Of RevenueMM
Stock Based Compensation To Revenue 0.05  0.05 
Sales General And Administrative To Revenue 0.14  0.13 
Research And Ddevelopement To Revenue 0.45  0.40 
Capex To Revenue 0.01  0.01 
Revenue Per Share 3.44  3.06 
Ebit Per Revenue 0.31  0.27 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Maze Therapeutics Common is a strong investment it is important to analyze Maze Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Maze Therapeutics' future performance. For an informed investment choice regarding Maze Stock, refer to the following important reports:
Check out the analysis of Maze Therapeutics Correlation against competitors.
You can also try the Money Managers module to screen money managers from public funds and ETFs managed around the world.
Will Pharmaceuticals sector continue expanding? Could Maze diversify its offerings? Factors like these will boost the valuation of Maze Therapeutics. Expected growth trajectory for Maze significantly influences the price investors are willing to assign. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Maze Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share
(2.56)
Return On Assets
(0.27)
Return On Equity
(0.53)
The market value of Maze Therapeutics Common is measured differently than its book value, which is the value of Maze that is recorded on the company's balance sheet. Investors also form their own opinion of Maze Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Maze Therapeutics' true underlying value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Because Maze Therapeutics' market value can be influenced by many factors that don't directly affect Maze Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Understanding that Maze Therapeutics' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Maze Therapeutics represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. Meanwhile, Maze Therapeutics' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.